ERCC1和BRCA1的表达可预测尿路上皮癌铂类化疗的预后。
The expression of ERCC1 and BRCA1 predicts prognosis of platinum-based chemotherapy in urothelial cancer.
作者信息
Song Wenhui, Ma Hongshun
机构信息
Department of Urology, Tianjin First Center Hospital, Tianjin, People's Republic of China.
出版信息
Onco Targets Ther. 2016 Jun 15;9:3465-71. doi: 10.2147/OTT.S101319. eCollection 2016.
OBJECTIVE
To investigate the expression and clinical significance of ERCC1 and BRCA1 genes in urothelial cancer patients.
METHODS
Forty-two urothelial cancer patients who did not receive platinum-based chemotherapy during January 2009 to May 2013 were enrolled. The expression levels of ERCC1 and BRCA1 were determined by immunohistochemistry and the median survival time (MST) for these patients was calculated.
RESULTS
ERCC1-positive patients who received oxaliplatin-based chemotherapy had a shorter MST than ERCC1-negative patients (P<0.05), whereas there is no difference of MST between BRCA1-positive and -negative patients. Furthermore, MST in ERCC1 and BRCA1 double-positive patients was shorter than ERCC1 and BRCA1 double-negative patients (P<0.05). The positive expression of ERCC1 had a significant positive correlation with BRCA1 (r=0.313, P=0.044).
CONCLUSION
The expression level of ERCC1 may be used as a prognostic marker for urothelial cancer patients who received postoperative adjuvant chemotherapy.
目的
探讨ERCC1和BRCA1基因在尿路上皮癌患者中的表达及其临床意义。
方法
纳入2009年1月至2013年5月期间未接受铂类化疗的42例尿路上皮癌患者。采用免疫组织化学法检测ERCC1和BRCA1的表达水平，并计算这些患者的中位生存时间（MST）。
结果
接受奥沙利铂化疗的ERCC1阳性患者的MST短于ERCC1阴性患者（P<0.05），而BRCA1阳性和阴性患者的MST无差异。此外，ERCC1和BRCA1双阳性患者的MST短于ERCC1和BRCA1双阴性患者（P<0.05）。ERCC1的阳性表达与BRCA1呈显著正相关（r=0.313，P=0.044）。
结论
ERCC1的表达水平可作为接受术后辅助化疗的尿路上皮癌患者的预后标志物。
Zotero 插件